AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06324357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study NCT06324357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan
Study NCT06324357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oropharyngeal swabs
Description: An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal swabs
Description: An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calcium score (CT scan)
Description: A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium score (CT scan)
Description: A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ECG
Description: Performed at inclusion, M6, M18 and M30
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG
Description: Performed at inclusion, M6, M18 and M30
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test
Description: Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
Study NCT06602934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test
Description: Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
Study NCT06603051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
Study NCT05803382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05803382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05803382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05803382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05803382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT
Study NCT05803382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05803382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06657612 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06605508 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction
Description: This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
Study NCT06605508 — intervention group
Intervention type: PROCEDURE
Intervention: Stem cell-derived Exosomes Injection for Erectile Dysfunction
Description: This intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
Study NCT06589635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC-189 and Itraconazole
Description: Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals.
Study NCT06588777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)
Description: transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
Study NCT05831124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose multivalent pneumococcal conjugate vaccine formulation B
Description: Biological
Study NCT05831124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of multivalent pneumococcal conjugate vaccine control
Description: low dose multivalent pneumococcal conjugate vaccine
Study NCT05831124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose multivalent pneumococcal conjugate vaccine control
Description: multivalent pneumococcal conjugate vaccine
Study NCT06588777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle
Study NCT06663332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study NCT06589687 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under neuraxial anesthetic.
Study NCT06590857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101
Description: Ac-225
Study NCT06593769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey-protein microgel
Description: The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.
Study NCT06593769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Water (isovoloumous amount)
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 Placebo
Description: Eye drop, single dose
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, three times daily for a total of 8 days
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, six times daily for a total of 8 days
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 Placebo
Description: Eye drop, multiple doses
Study NCT06597422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0902 ophthalmic solution
Description: Eye drop, single dose, tear samples will be collected
Study NCT06609213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.
Study NCT06658431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music group therapy
Description: 90 minutes music group therapy
Study NCT05969990 — intervention group
Intervention type: OTHER
Intervention: tryptophan metabolites in plasma
Description: we will investigate the tryptophan metabolites in plasma of children with migraine
Study NCT04680533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
Study NCT04778839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Micelles for Injection
Description: Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
Study NCT06657248 — intervention group
Intervention type: DEVICE
Intervention: univation® XF Pro
Description: Primary medial unicompartmental knee arthroplasty
Study NCT06588608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular nerve stimulation (aVNS)
Description: The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
Study NCT06588608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham aVNS
Description: The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
Study NCT05535816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
Study NCT06670027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family voice
Description: Group A receives the family voice
Study NCT06670027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nature sound
Description: Group B receives the nature sound.
Study NCT04857827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Study NCT04857827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate PF 0.5% ophthalmic solution
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Study NCT05562739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
Study NCT05562739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in a form of a capsule for 6 weeks.
Study NCT06617195 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
Study NCT04898400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy sleeve gastroplasty
Description: endoscopic procedure for weight loss
Study NCT05039840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 IV
Description: Pharmaceutical form: solution Route of administration: Intravenous infusion
Study NCT05039840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 SC
Description: Pharmaceutical form: solution Route of administration: subcutaneous injection
Study NCT05039840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Pharmaceutical form: solution Route of administration: Intravenous infusion
Study NCT05039840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Pharmaceutical form: solution Route of administration: subcutaneous injection
Study NCT06675942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion
Description: The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.
Study NCT06675942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation
Description: High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
Study NCT06342921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg ADC189
Description: Use only once during the whole study.
Study NCT06342921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg ADC189
Description: Use only once during the whole study.
Study NCT06342921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use only once during the whole study.
Study NCT04778839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
Study NCT06619236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rina-S
Description: Intravenous (IV) infusion
Study NCT06619236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT06619236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV infusion
Study NCT06619236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: IV infusion
Study NCT06619236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT06608212 — intervention group
Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY948862)
Description: Follow clinical practice/administration.
Study NCT06608212 — intervention group
Intervention type: DRUG
Intervention: Others except finerenone
Description: Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
Study NCT06684470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: mirtazapine will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
Study NCT06684470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
Study NCT06684028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-JNU
Description: Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Study NCT06686927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids combined with immunoglobulin and romiplostim
Description: Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month.
Study NCT06687772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.
Study NCT06687772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.
Study NCT06687772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Infusion of autologous peripheral blood stem cells on Day 0.
Study NCT06687772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline-based induction chemotherapy
Description: Standard of care, not dictated by protocol.
Study NCT06685913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone supplement
Description: 100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test
Study NCT06685913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
Study NCT06624072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 1
Description: Reference treatment (R)
Study NCT06382129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.